Remedium Capital Partners, LLC
Remedium Capital Partners, LLC reported 6 positions worth $273.6M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: SYRE (37.8%). Biggest move: exit Apogee Therapeutics Inc ($77.9M).
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Remedium Capital Partners, LLC hold as of Q3 2026?
Remedium Capital Partners, LLC reported 6 positions worth $273.6M in its Q3 2026 13F filing. Largest positions: SYRE (37.8%), ORKA (29.0%), DMRA (15.9%), JBIO (9.3%) and KRSA (6.1%).
What did Remedium Capital Partners, LLC buy in Q3 2026?
New positions: DMRA and KRSA. Added to: JBIO.
What did Remedium Capital Partners, LLC sell in Q3 2026?
Reduced: ORKA and SYRE. Sold out entirely: Apogee Therapeutics Inc and Damora Therapeutics Inc.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.